Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcbest (ARCB) Asset Writedowns and Impairment (2016 - 2025)

Arcbest (ARCB) has disclosed Asset Writedowns and Impairment for 17 consecutive years, with $9.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Asset Writedowns and Impairment rose 2955.33% to $9.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $12.0 million, a 608.06% increase, with the full-year FY2025 number at $12.0 million, up 608.06% from a year prior.
  • Asset Writedowns and Impairment was $9.7 million for Q4 2025 at Arcbest, up from $984000.0 in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $30.2 million in Q3 2023 to a low of -$338000.0 in Q4 2024.
  • A 5-year average of $2.8 million and a median of $1.1 million in 2024 define the central range for Asset Writedowns and Impairment.
  • Peak YoY movement for Asset Writedowns and Impairment: tumbled 116.58% in 2024, then surged 2955.33% in 2025.
  • Arcbest's Asset Writedowns and Impairment stood at $1.5 million in 2021, then rose by 24.1% to $1.9 million in 2022, then increased by 7.83% to $2.0 million in 2023, then tumbled by 116.58% to -$338000.0 in 2024, then soared by 2955.33% to $9.7 million in 2025.
  • Per Business Quant, the three most recent readings for ARCB's Asset Writedowns and Impairment are $9.7 million (Q4 2025), $984000.0 (Q3 2025), and $273000.0 (Q2 2025).